252 related articles for article (PubMed ID: 19043921)
1. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Lai MW; Yeh CT
Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
[TBL] [Abstract][Full Text] [Related]
2. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.
Lai MW; Huang SF; Hsu CW; Chang MH; Liaw YF; Yeh CT
Antivir Ther; 2009; 14(2):249-61. PubMed ID: 19430100
[TBL] [Abstract][Full Text] [Related]
3. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
4. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
Yeh CT
Antivir Ther; 2010; 15(3 Pt B):471-5. PubMed ID: 20516567
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma.
Yeh CT; Shen CH; Tai DI; Chu CM; Liaw YF
Oncogene; 2000 Nov; 19(46):5213-20. PubMed ID: 11077437
[TBL] [Abstract][Full Text] [Related]
6. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
Warner N; Locarnini S
Hepatology; 2008 Jul; 48(1):88-98. PubMed ID: 18537180
[TBL] [Abstract][Full Text] [Related]
7. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
8. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage.
Hsieh YH; Su IJ; Wang HC; Chang WW; Lei HY; Lai MD; Chang WT; Huang W
Carcinogenesis; 2004 Oct; 25(10):2023-32. PubMed ID: 15180947
[TBL] [Abstract][Full Text] [Related]
9. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
10. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
[TBL] [Abstract][Full Text] [Related]
11. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
Wang ML; Tang H
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846
[TBL] [Abstract][Full Text] [Related]
12. [Construction of whole-genome lamivudine-resistant hepatitis B virus mutant and its replication and expression in HepG2 cells].
Sun J; Wang C; Wen SJ; Wang ZH; Hou JL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):991-3. PubMed ID: 17666334
[TBL] [Abstract][Full Text] [Related]
13. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
14. Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis.
Caselmann WH
J Hepatol; 1995; 22(1 Suppl):34-7. PubMed ID: 7602073
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
Villet S; Billioud G; Pichoud C; Lucifora J; Hantz O; Sureau C; Dény P; Zoulim F
Gastroenterology; 2009 Jan; 136(1):168-176.e2. PubMed ID: 18996386
[TBL] [Abstract][Full Text] [Related]
16. Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA.
Shouval D; Reid LM; Chakraborty PR; Ruiz-Opazo N; Morecki R; Gerber MA; Thung SN; Shafritz DA
Cancer Res; 1981 Apr; 41(4):1342-50. PubMed ID: 6260336
[TBL] [Abstract][Full Text] [Related]
17. Deletion of integrated hepatitis B virus genome and cellular flanking sequences in hepatocellular carcinoma cells in BALB/c mice.
Chang PC; Hu CP; Chen SH; Wang-Wuu S; Chang C
Hepatology; 1995 Jun; 21(6):1504-9. PubMed ID: 7768493
[TBL] [Abstract][Full Text] [Related]
18. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection.
Sengupta S; Rehman S; Durgapal H; Acharya SK; Panda SK
J Med Virol; 2007 Mar; 79(3):220-8. PubMed ID: 17245717
[TBL] [Abstract][Full Text] [Related]
19. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
20. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
Yeh CT; Chen T; Hsu CW; Chen YC; Lai MW; Liang KH; Chen TC
BMC Cancer; 2011 Sep; 11():398. PubMed ID: 21933446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
